Huang Hua, Ji Lijiang, Gu Yunfei, Li Youran, Xu Shanshan
Department of Anorectal, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu, China.
Department of Anorectal, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Front Surg. 2022 Feb 8;9:825166. doi: 10.3389/fsurg.2022.825166. eCollection 2022.
There are many surgical methods of sphincter preservation in treating complex anal fistula, but the therapeutic effects of each operation are different. Therefore, this study aimed to compare the impact of other treatment methods through a network meta-analysis to evaluate the best sphincter preservation method for treating complex anal fistula.
We searched PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, VIP Journal Database, and the Wanfang Database to collate randomized controlled trials on sphincter-preserving surgery for complex anal fistula.
A total of 29 articles were included in this meta-analysis. The cure rates showed no statistically significant differences between any two interventions ( > 0.05). The recurrence rate results showed that the rate of patients after Fistulectomy was higher than others ( < 0.05). The incidence rate of complications showed that the incidence rate after fistulectomy treatment was higher than that of others ( < 0.05). The surface under the cumulative ranking (SUCRA) was used to arrange their advantages and disadvantages, and a larger SUCRA value indicates that the intervention may be more effective. The results showed that TROPIS may have the highest cure rate (SUCRA = 78.6%), stem cell transplantation (SCT) may have the lowest recurrence rate (SUCRA = 85.5%), and imLIFT may have the least complications (SUCRA = 88.2%).
According to the existing literature data, for patients with complex anal fistula, TROPIS may be the surgical method with the highest cure rate, SCT may be the treatment method with the lowest recurrence rate, and imLIFT may be the surgical method with the lowest incidence of postoperative complications.
PROSPERO, identifier: CRD42020221907.
治疗复杂性肛瘘有多种保留括约肌的手术方法,但每种手术的治疗效果不同。因此,本研究旨在通过网状Meta分析比较其他治疗方法的影响,以评估治疗复杂性肛瘘的最佳保留括约肌方法。
我们检索了PubMed、Embase、Cochrane图书馆、中国知网、中国生物医学文献数据库、维普期刊数据库和万方数据库,以整理关于复杂性肛瘘保留括约肌手术的随机对照试验。
本Meta分析共纳入29篇文章。治愈率显示,任何两种干预措施之间均无统计学显著差异(>0.05)。复发率结果显示,瘘管切除术后患者的复发率高于其他患者(<0.05)。并发症发生率显示,瘘管切除术后的发生率高于其他患者(<0.05)。采用累积排序曲线下面积(SUCRA)来排列它们的优缺点,SUCRA值越大表明干预措施可能越有效。结果显示,TROPIS可能具有最高的治愈率(SUCRA = 78.6%),干细胞移植(SCT)可能具有最低的复发率(SUCRA = 85.5%),改良推移皮瓣内口结扎术(imLIFT)可能具有最少的并发症(SUCRA = 88.2%)。
根据现有文献数据,对于复杂性肛瘘患者,TROPIS可能是治愈率最高的手术方法,SCT可能是复发率最低的治疗方法,imLIFT可能是术后并发症发生率最低的手术方法。
PROSPERO,标识符:CRD42020221907。